Idorsia Ltd Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/9/2026)
| Balance Sheet | Total Assets | 465,878,000.00 | ROE | -244.09 % |
| Balance Sheet | Total Equity | -1,137,170,000.00 | ROA | -24.04 % |
| Cashflow | Capital Expenditures | -13,820,000.00 | P/FCF | -5.44 |
| Cashflow | Free Cash Flow | -167,047,008.00 | – | – |
| Cashflow | Operating Cash Flow | -153,227,000.00 | P/CF | -5.94 |
| Income | Earnings per Share (diluted) | -0.52 | Div. Yield | – |
| Income | Net Income | -112,000,000.00 | P/E | -8.15 |
| Income | Shares Outstanding | 214,700,000.00 | P/B | -0.80 |
| Income | Total Revenue | 221,000,000.00 | P/S | 4.12 |
Ratios calculated on: 10/14/2026
Company Description
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.idorsia.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more